Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.64 |
| ▸ | PDE4A | P27815 | 8/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Methylxanthine SCHEMBL9317914 | 0.98 | ADORA2A (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL30753411 | 0.98 | ADORA2A (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL4020124 | 0.98 | ADORA2A (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL2791774 | 0.89 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL1892894 | 0.88 | ADORA2B (0.77) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| 3-Methylxanthine SCHEMBL4018085 | 0.88 | ADORA2A (0.52) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| Theobromine SCHEMBL4024314 | 0.87 | MAPK1 (0.75) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17164064 | 0.85 | ATAD2 (0.51) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL864455 | 0.81 | ADORA2A (0.58) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| Caffeine SCHEMBL17748263 | 0.81 | ADORA2A (0.61) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1700 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122013188-A | One-step etching solution for Cu alloy oxide and preparation method thereof | 南京和显达微电子科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | claimed |
| CN-120084902-A | Biomarker for predicting colchicine preventive response of gout patient and application thereof | 查理高特(青岛)健康科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| CN-119936223-A | Metabolic marker for diagnosing or monitoring gastric cancer, screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2025068213-A1 | USE OF A MARKER SET FOR DETERMINING THE RISK OF HAVING OR DEVELOPING BLADDER CANCER | NUMARES AG (DE) | 2025-04-03 | — | — | WO | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-119039294-B | Preparation method of 3, 7-dimethyl xanthine | 石药创新制药股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| EP-0315401-A2 | Xanthine derivatives and their preparation and pharmaceutical formulation | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1989-05-10 | — | — | EP | claimed |
| EP-0098179-B1 | HYBRIDOMA CELL LINES AND MONOCLONAL ANTIBODIES TO THEOPHYLLINE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-15 | — | — | EP | claimed |
| CN-1031184-A | Pharmaceutical composition and preparation thereof and application | HOECHST AG (DE) | 1989-02-22 | — | — | CN | claimed |
| CN-87107785-A | OXADIAZOLE-ALKYL-PURINE DERIVATIVES | — | 1988-07-20 | — | — | CN | claimed |
| EP-0264081-A2 | Oxadiazolyl alkyl purin derivatives, their preparation and their use in pharmaceutical compositions | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1988-04-20 | — | — | EP | claimed |
| EP-0019165-B1 | PROCESS FOR PREPARING 1,3,7-TRIALKYLXANTHINES | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1985-07-31 | — | — | EP | claimed |
| US-4524025-A | Hybridoma cell lines and monoclonal antibodies to theophylline | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-06-18 | — | — | US | claimed |
| US-4521510-A | IMMUNDASSAY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-06-04 | — | — | US | claimed |
| US-4450163-A | ANTIBODY INHIBITORS; N-ALKYLATION OF XANTHINES USING PHASE TRANSFER AGENTS | SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) | 1984-05-22 | — | — | US | claimed |
| EP-0098179-A2 | Hybridoma cell lines and monoclonal antibodies to theophylline | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | ADORA2A 1643/4885PDE4A 3643/4885PDE4B 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.